TRPM2 mediates histone deacetylase inhibition-induced apoptosis in bladder cancer cells

Cancer Biotherapy and Radiopharmaceuticals

Volumn 30, Issue 2, 2015, Pages 87-93

  Cao, Qi Feng ^a   Qian, Su Bo ^a   Wang, Ning ^a   Zhang, Liang ^a   Wang, Wei Ming ^a   Shen, Hai Bo ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

apoptosis; bladder cancer; HDAC inhibitor; TRPM2

Indexed keywords

BUTYRIC ACID; CASPASE 8; HISTONE DEACETYLASE; PROCASPASE 8; SHORT HAIRPIN RNA; TRANSIENT RECEPTOR POTENTIAL CHANNEL M2; TRICHOSTATIN A; HISTONE DEACETYLASE INHIBITOR; HYDROXAMIC ACID; TRANSIENT RECEPTOR POTENTIAL CHANNEL M; TRPM2 PROTEIN, HUMAN;

APOPTOSIS; ARTICLE; BLADDER CANCER; BLADDER CANCER CELL LINE; CELL SURVIVAL; CHROMATIN IMMUNOPRECIPITATION; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME INDUCTION; ENZYME INHIBITION; FLOW CYTOMETRY; GENE EXPRESSION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; REAL TIME POLYMERASE CHAIN REACTION; TRANSIENT TRANSFECTION; BLADDER TUMOR; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; PATHOLOGY; PROMOTER REGION; TUMOR CELL LINE; UPREGULATION;

APOPTOSIS; BUTYRIC ACID; CELL LINE, TUMOR; GENE EXPRESSION REGULATION, NEOPLASTIC; HISTONE DEACETYLASE INHIBITORS; HISTONE DEACETYLASES; HUMANS; HYDROXAMIC ACIDS; PROMOTER REGIONS, GENETIC; TRPM CATION CHANNELS; UP-REGULATION; URINARY BLADDER NEOPLASMS;

EID: 84924573885     PISSN: 10849785     EISSN: 15578852     Source Type: Journal    
DOI: 10.1089/cbr.2014.1697     Document Type: Article

References (38)

1. Kaufman DS, Shipley WU, Feldman AS. Bladder cancer. Lancet 2009; 374: 239.
2. Kirkali Z, Chan T, Manoharan M, et al. Bladder cancer: Epidemiology, staging and grading, and diagnosis. Urology 2005; 66 (6 suppl 1): 4.
3. Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin 2011; 61: 69.
4. Lehmann J, Retz M, Stockle M. Is there standard chemotherapy for metastatic bladder cancer? Quality of life and medical resources utilization based on largest to date randomized trial. Crit Rev Oncol Hematol 2003; 47: 171.
5. Fukushima S, Wanibuchi H. Prevention of urinary bladder cancer: The interface between experimental and human studies. Asian Pac J Cancer Prev 2000; 1: 15.
6. Grunstein M. Histone acetylation in chromatin structure and transcription. Nature 1997; 389: 349.
7. Brown R, Strathdee G. Epigenomics and epigenetic therapy of cancer. Trends Mol Med 2002; 8 (4 suppl): S43.
8. Schweiger MR, Barmeyer C, Timmermann B. Genomics and epigenomics: New promises of personalized medicine for cancer patients. Brief Funct Genomics 2013; 12: 411.
9. Qin HX, Cui HK, Pan Y, et al. HDAC6 siRNA inhibits proliferation and induces apoptosis of HeLa cells and its related molecular mechanism. Asian Pac J Cancer Prev 2012; 13: 3367.
10. Li N, Tie XJ, Liu PJ, et al. Effects of down-regulation of HDAC6 expression on proliferation, cell cycling and migration of esophageal squamous cell carcinoma cells and related molecular mechanisms. Asian Pac J Cancer Prev 2013; 14: 685.
11. Lin RJ, Nagy L, Inoue S, et al. Role of the histone deacetylase complex in acute promyelocytic leukaemia. Nature 1998; 391: 811.
12. Johnstone RW. Histone-deacetylase inhibitors: Novel drugs for the treatment of cancer. Nat Rev Drug Discov 2002; 1: 287.
13. Takai N, Kira N, Ishii T, et al. Novel chemotherapy using histone deacetylase inhibitors in cervical cancer. Asian Pac J Cancer Prev 2011; 12: 575.
14. Sriraksa R, Limpaiboon T. Histone deacetylases and their inhibitors as potential therapeutic drugs for cholangiocarcinoma- cell line findings. Asian Pac J Cancer Prev 2013; 14: 2503.
15. Zhang QC, Jiang SJ, Zhang S, Ma XB. Histone deacetylase inhibitor trichostatin A enhances anti-tumor effects of docetaxel or erlotinib in A549 cell line. Asian Pac J Cancer Prev 2012; 13: 3471.
16. Cheng DD, Yang QC, Zhang ZC, et al. Antitumor activity of histone deacetylase inhibitor trichostatin A in osteosarcoma cells. Asian Pac J Cancer Prev 2012; 13: 1395.
17. Gui CY, Ngo L, Xu WS, et al. Histone deacetylase (HDAC) inhibitor activation of p21WAF1involves changes in promoterassociated proteins, including HDAC1. Proc Natl Acad Sci U S A 2004; 101: 1241.
18. Richon VM, Sandhoff TW, Rifkind RA, Marks PA. Histone deacetylase inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation. Proc Natl Acad Sci U S A 2000; 97: 10014.
19. Archer SY, Meng S, Shei A, Hodin RA. p21 (WAF1) is required for butyrate-mediated growth inhibition of human colon cancer cells. Proc Natl Acad Sci U S A 1998; 95: 6791.
20. Shankar S, Srivastava RK. Histone deacetylase inhibitors: Mechanisms and clinical significance in cancer: HDAC inhibitor-induced apoptosis. Adv Exp Med Biol 2008; 615: 261.
21. Nasif WA, El-Emshaty HM, Lotfy M, et al. Apoptosis dysregulation in human gastric carcinomas: Relationship to anti- and pro-apoptotic protein expression. Asian Pac J Cancer Prev 2007; 8: 45.
22. Glaser KB, Staver MJ, Waring JF, et al. Gene expression profiling of multiple histone deacetylase (HDAC) inhibitors: Defining a common gene set produced by HDAC inhibition in T24 and MDA carcinoma cell lines. Mol Cancer Ther 2003; 2: 151.
23. Xu C, Macciardi F, Li PP, et al. Association of the putative susceptibility gene, transient receptor potential protein melastatin type 2, with bipolar disorder. Am J Med Genet B Neuropsychiatr Genet 2006; 141B: 36.
24. Zhong Z, Zhai Y, Liang S, et al. TRPM2 links oxidative stress to NLRP3 inflammasome activation. Nat Commun 2013; 4: 1611.
25. Miller BA. The role of TRP channels in oxidative stressinduced cell death. J Membr Biol 2006; 209: 31.
26. Csanady L, Torocsik B. Four Ca2 + ions activate TRPM2 channels by binding in deep crevices near the pore but intracellularly of the gate. J Gen Physiol 2009; 133: 189.
27. Zhang W, Hirschler-Laszkiewicz I, Tong Q, et al. TRPM2 is an ion channel that modulates hematopoietic cell death through activation of caspases and PARP cleavage. Am J Physiol Cell Physiol 2006; 290: C1146.
28. Wong P, Taillefer D, Lakins J, et al. Molecular characterization of human TRPM-2/clusterin, a gene associated with sperm maturation, apoptosis and neurodegeneration. Eur J Biochem 1994; 221: 917.
29. Kaneko S, Kawakami S, Hara Y, et al. A critical role of TRPM2 in neuronal cell death by hydrogen peroxide. J Pharmacol Sci 2006; 101: 66.
30. Buttyan R, Olsson CA, Pintar J, et al. Induction of the TRPM-2 gene in cells undergoing programmed death. Mol Cell Biol 1989; 9: 3473.
31. Carew JS, Giles FJ, Nawrocki ST. Histone deacetylase inhibitors: Mechanisms of cell death and promise in combination cancer therapy. Cancer Lett 2008; 269: 7.
32. Butler LM, Zhou X, Xu WS, et al. The histone deacetylase inhibitor SAHA arrests cancer cell growth, up-regulates thioredoxin-binding protein-2, and down-regulates thioredoxin. Proc Natl Acad Sci U S A 2002; 99: 11700.
33. Jeon YJ, Ko SM, Cho JH, et al. The HDAC inhibitor, panobinostat, induces apoptosis by suppressing the expresssion of specificity protein 1 in oral squamous cell carcinoma. Int J Mol Med 2013; 32: 860.
34. Borutinskaite VV, Magnusson KE, Navakauskiene R. Histone deacetylase inhibitor BML-210 induces growth inhibition and apoptosis and regulates HDAC and DAPC complex expression levels in cervical cancer cells. Mol Biol Rep 2012; 39: 10179.
35. Sharma V, Koul N, Joseph C, et al. HDAC inhibitor, scriptaid, induces glioma cell apoptosis through JNK activation and inhibits telomerase activity. J Cell Mol Med 2010; 14: 2151.
36. Elmore S. Apoptosis: A review of programmed cell death. Toxicol Pathol 2007; 35: 495.
37. Sun L, Yau HY, Wong WY, et al. Role of TRPM2 in H (2)O (2)-induced cell apoptosis in endothelial cells. PLoS One 2012; 7: e43186.
38. Orrenius S, Zhivotovsky B, Nicotera P. Regulation of cell death: The calcium-apoptosis link. Nat Rev Mol Cell Biol 2003; 4: 552.